Disease · MONDO_0004950
gastric carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. gastric carcinoma. Diseases, record MONDO_0004950. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004950
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Ca fundus - stomach, cancer of fundus of stomach, carcinoma of stomach, carcinoma of the stomach, fundus of stomach cancer, gastric fundus cancer, malignant fundus of stomach neoplasm, malignant neoplasm of fundus of stomach, malignant tumor of fundus of stomach, stomach carcinoma
- Open Targets
Drugs46
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ROFECOXIB | CHEMBL122 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| TEGAFUR | CHEMBL20883 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| GIMERACIL | CHEMBL1730601 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| RIVOCERANIB | CHEMBL3186534 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 46
See all 46 drugsTargets69
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| TYMS | Thymidylate synthase | 4 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 3 | Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 1/2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| ERBB2 | ErbB-2/ErbB-3 heterodimer | 3 | ErbB-2/ErbB-3 heterodimer inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| TUBA1A | Tubulin | 3 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 3 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 3 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 3 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 3 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 3 | Tubulin disrupting agent; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
1 to 10 of 69
See all 69 targetsTrials35
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01743469 | A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers | Phase 2 | 201 | 2018-05-07 | Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer, Advanced or Metastatic Gastric Carcinoma | TASQUINIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT01774851 | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | Phase 2 | 84 | 2017-06-22 | HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer | MM-111, PACLITAXEL, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | Phase 1/2 | 76 | 2025-03-17 | Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor | ETIGILIMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03449030 | A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC) | Phase 1 | 31 | 2021-03-22 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TAK-164 | Its record names the disease | ClinicalTrials.gov |
| NCT00607594 | Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer | Phase 2 | 21 | 2014-07-18 | Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer, Stage III Esophageal Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer | SARACATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors | Phase 1/2 | 747 | Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural | AVELUMAB, REGORAFENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT01248403 | A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy | Phase 3 | 300 | Advanced Gastric Cancer, Esophagogastric Junction Cancer | EVEROLIMUS, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00005060 | Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer | Phase 3 | 240 | Gastric Cancer | CISPLATIN, DOCETAXEL, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT04984668 | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | Phase 1/2 | 216 | Solid Tumor | ASCRINVACUMAB, ERFONRILIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00164892 | Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial | Phase 3 | 214 | Cancer of Stomach | ROFECOXIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Experimental Group vs Control Group: deaths from any cause | 11 of 42 | 18 of 42 | 84 | NCT01774851 | Trial comparisons |
| Experimental Group vs Control Group: serious adverse events | 19 of 42 | 16 of 42 | 84 | NCT01774851 | Trial comparisons |
Papers from its trials13
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 20231677 | RESULT | 1 | PubMed |
| 17664469 | RESULT | 1 | PubMed |
| 40880848 | DERIVED | 1 | PubMed |
| 40579407 | DERIVED | 1 | PubMed |
| 40204996 | DERIVED | 1 | PubMed |
| 36738333 | DERIVED | 1 | PubMed |
| 34998048 | DERIVED | 1 | PubMed |
| 34965951 | DERIVED | 1 | PubMed |
| 32898333 | DERIVED | 1 | PubMed |
| 32788205 | DERIVED | 1 | PubMed |
1 to 10 of 13
See all 13 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004950
GET https://conductscience.org/api/diseases/v1/MONDO_0004950/drugs?page=2